Impavido

Chemical Namemiltefosine
Dosage FormCapsule (oral; 50 mg)
Drug ClassAntiprotozoals
SystemBlood, Skin, Respiratory
CompanyProfounda
Approval Year2014

Indication

  • For treatment of visceral leishmaniasis due to Leishmania donovani in adults and adolescents ≥12 years of age weighing ≥30 kg.
  • For treatment of cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis in adults and adolescents ≥12 years of age weighing ≥30 kg.
  • For treatment of mucosal leishmaniasis due to Leishmania braziliensi in adults and adolescents ≥12 years of age weighing ≥30 kg.
Last updated on 7/18/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Impavido (miltefosine) Prescribing Information.2021Profounda, Inc., Orlando, FL